2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 53

Spine-Hip Diagnostic Discordance in the United Arab Emirates
Abstract Number: 1450

Spironolactone As a Novel DMARD in Rheumatoid Arthritis
Abstract Number: 710

Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis
Abstract Number: 2829

Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Abstract Number: 1398

Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal
Abstract Number: 443

Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis
Abstract Number: 1761

Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application
Abstract Number: 1858

Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic
Abstract Number: 2319

Standardizing and Documenting Patient Education and Disease Indices in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1777

Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Abstract Number: 663

STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice
Abstract Number: 1033

Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling
Abstract Number: 1815

STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation
Abstract Number: 3009

Stem Cell Augmentation for Cardiovascular Risk in Rheumatoid Arthritis
Abstract Number: 1457

Stem Cell Growth Factor Expression in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].